Semax Research Overview
An overview of Semax, a synthetic ACTH analogue, and its role in cognitive and neurological research.
Scientific background / literature overview only. Discussion of published research does not describe the intended use of Novex Peptide products.
Introduction
> **Research Context Notice** — This article summarises published scientific literature for educational and research-reference purposes only. Discussion of experimental, preclinical or clinical findings does not represent a permitted use of Novex Peptide products. Products supplied by Novex Peptide are intended exclusively for in-vitro laboratory research and are not intended for human or animal administration.
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH). Developed in Russia in the 1980s, it has been studied for its effects on cognitive function, memory, and neuroprotection in animal and in vitro models.
Mechanism of Action
ACTH Fragment Activity
Semax corresponds to amino acids 4-10 of ACTH. Unlike full-length ACTH, Semax lacks corticosteroid-stimulating activity but retains neurotrophic and cognitive effects observed in animal studies.
BDNF Expression
Research indicates Semax may upregulate brain-derived neurotrophic factor (BDNF) expression in the hippocampus and frontal cortex in animal models.
Serotonergic and Dopaminergic Systems
Animal studies suggest Semax may influence serotonin and dopamine neurotransmitter systems, though the precise mechanisms remain under investigation.
Current Research
Cognitive Research
Animal studies have investigated Semax's effects on learning, memory consolidation, and attention using various behavioural paradigms.
Neuroprotection Research
In vitro and animal studies have explored Semax's potential neuroprotective effects in models of oxidative stress, hypoxia, and excitotoxicity.
Pain Research
Some research has investigated Semax's effects on pain perception and analgesia in animal models.
Chemical Properties
Reference values describe the named molecular form in [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/9811102). Salt, counterion, hydration and formulation may change the mass of supplied material. Confirm the supplied form before quantitative use.
Storage Considerations
Follow the supported product label and compound-specific laboratory protocol. Solution stability depends on the exact material, solvent, concentration and storage conditions; there is no universal refrigerated shelf life or freezing protocol. Obtain missing stability information before preparation. Where validated, use aliquots to minimise repeated freeze-thaw cycles.
Testing Methods
Semax batches should be verified by:
Research Limitations
Semax is supplied for in-vitro laboratory research only. Published preclinical literature includes in-vivo animal studies. References to such studies are provided solely as scientific background and do not indicate that Novex Peptide products are supplied for animal administration. Most published research originates from Russian research groups. No clinical trials outside Russia have confirmed efficacy. No medical, therapeutic, or dosing claims are made. Semax is not approved for human therapeutic use by Western regulatory authorities.
References
- 1.Asadulaeva ZM, et al. Semax and Cognitive Function. Bull Exp Biol Med. 2011;151(4):425-428.
- 2.Kaplan AY, et al. Semax: 25 Years of Research. Acta Naturae. 2019;11(2):18-25.
- 3.Dolotov OV, et al. Semax and BDNF. Mol Genet Mikrobiol Virusol. 2006;(4):31-35.
Research use only. This article is for educational purposes only and does not constitute advice for any application involving human use. No medical claims are made.
